Technologies that integrate diagnostics with therapeutics comprise the nascent and exciting field of theranostics, which promises to enable disease treatment immediately following discovery.
Diagnostics and therapeutics, they go together like…a horse and carriage? Well, maybe not linguistically, but more and more frequently, diagnostic and imaging agents are also serving as agents of therapy and disease elimination. And where these two roads meet, the emerging field of “theranostics” begins.
The field includes laser-activated nanoparticles that work to enable imaging of tissue and—once disease is found—to destroy the unhealthy cells.
“Theranostics is a tall order for tiny nanoparticles,” says Xiaoyuan (Shawn) Chen, Sr., investigator and chief of the Laboratory of Molecular Imaging and Nanomedicine at the National Institutes of Health (Bethesda, MD). “Not only must those particles enable imaging in real time and then deliver a therapeutic response, they must also be safely eliminated from the body.” In addition to his work at the NIH, Chen serves as the editor of Theranostics (www.thno.org), an open-access journal that launched in 2011.
|FIGURE 1. Nanocomplexes delivered in-vivo are observed with near-IR fluorescence imaging of mice for control, low HER 2 expressing tumors (top row) and HER 2 expressing tumors (bottom row). HER 2 is a type of antibody that targets breast cancer. The animals were imaged at 0.3, 2, 4, 24, 48, and 72 hours postinjection. Fluorescence intensity comparison of tumors between the HER 2 expressing tumors and control shows a 71.5% increase in signal at 4 h in HER 2 expressing over the control tumors. The dotted line is a guide to the eye. (Courtesy of Rice University)|
According to Chen, the “formula” of the nanoparticle is critical, since it must accommodate just the right peptides or proteins to find disease and support imaging requirements (using visible, fluorescent, or molecular imaging methodologies)—and also enable therapy or drug delivery.
“Although nanoparticles are readily available for industrial and cosmetic purposes, they have a long way to go in medical applications,” adds Chen. “Fortunately, all pharmaceutical companies have imaging diagnostic centers that are driving the development of theranostics to determine the efficacy of drugs in preclinical settings. And academic institutions are furthering the effort with breakthrough discoveries.” For example, Rice University (Houston, TX) is exploring cancer-targeting gold nanoparticles that form laser-induced nanobubbles to image cancer at low light levels and burst to destroy cancer at higher illumination levels.
The power of the particle
In addition to creating gold nanoparticles that kill cancer cells via laser-induced nanobubbles, Rice University researchers in the Laboratory for Nanophotonics (LANP), along with researchers from Baylor College of Medicine (BCM) and the University of Texas (UT) MD Anderson Cancer Center (all in Houston, TX), have created nanoparticles that kill cancer cells with heat. The researchers are the recipients of a five-year, $1.8 million grant from the National Cancer Institute’s (NCI) Alliance for Nanotechnology in Cancer program that will fund preclinical testing for theranostic treatment of pancreatic cancer—a difficult-to-treat and deadly form of cancer with a postsurgical survival rate of less than 25%.1
Invented by Naomi Halas, Stanley C. Moore Professor in Electrical and Computer Engineering and professor of chemistry and biomedical engineering at Rice University, the cancer-seeking, cancer-killing nanoparticles typically consist of a spherical silica core wrapped in a several-nanometer-thick gold shell.2 A thin dielectric layer applied over the nanoshell absorbs near-infrared (IR) fluorophores such as indocyanine green (ICG) that are used as contrast agents for fluorescence imaging (see Fig. 1). The nanoparticles can also be seeded with active markers for magnetic resonance imaging (MRI) to track the nanoparticles throughout the body and observe their distribution within tumors before, during and after treatment. After a tumor absorbs sufficient numbers of nanoparticles that can be tagged with antibodies to seek specific cancer types, illumination of the cancer site with near-IR (650–950 nm) light causes nanoparticle heating (nanoshells are an excellent near-IR absorber) and tumor-cell destruction.
Halas’ gold nanoshells have already proven effective in eradicating tumors in laboratory animals.3 In a 2004 animal trial with 25 mice with tumors ranging in size from 3 to 5.5 mm, the group of animals that received nanoshell injections and, six hours later, near-IR irradiation (from a 5 mm wide beam) of the skin over the tumor site had no detectable tumors (and no skin damage) two weeks after the photothermal treatment. Surface temperature measurements taken on the skin above the tumors during laser treatment showed an average temperature rise of 46ºF.
Nanospectra Biosciences (Houston, TX), who worked with Rice University on the 2004 small-animal trial, recently demonstrated nanoparticle-directed ablation of the canine prostate in collaboration with colleagues at BCM and UT.4 Illumination of 150-nm-diameter nanoshell particles injected directly into canine prostate glands was delivered by a 15 W, 810 ± 20 nm laser (Diomed) input to a 400-µm-core optical fiber catheter terminated with a 1 cm isotropic diffuser. The catheter—with 3.0 and 3.5 W average-power output—was passed through the affected prostate in a controlled manner. In this study, the nanoshells were not designed to specifically target cancerous tumors, but serve merely as a proxy for eventual cancer-seeking nanoshells that would accumulate within cancerous tissue, as the intent is to show the effectiveness of localized nanoparticle ablation. The study showed that 3 W power levels, only marginally ablative to normal tissues, cause localized heating of the near-IR absorptive nanoparticles and create radial lesions confined to within 4 mm of the optical catheter with sub-millimeter accuracy. “We have demonstrated intravenous particle delivery in numerous animal models as well as squamous cell tumors in humans,” says Donald Payne, president and CEO of Nanospectra Biosciences. “This canine study prepares us for a study in human prostate cancer,” he adds.
|FIGURE 2. Photosensitized (with chlorine e6 or Ce6) human blood proteins (human serum albumin or HSA) can be used to image cancer cells and produce singlet oxygen upon exposure to radiation, visibly killing tumor cells. Images of in-vivo photodynamic therapy (a) are shown after intravenous injection of both the control photosensitizer Ce6 and Ce6-HSA nanoparticles with 30 min irradiation of the tumor site with a 671 nm, 6 J/cm2 laser. Tumor growth data (b) is measured for 25 days. After 10 days of treatment, stained tumor tissue (c) confirms the tumor treated with Ce6-HAS nanoparticles is destroyed. Original magnification is 100X. (Courtesy of Korea Institute of Science and Technology and Kyung Hee University)|
Another dramatic tumor-eradication method from researchers at the Korea Institute of Science and Technology and Kyung Hee University (both in Seoul, Korea) uses a hydrophobic photosensitizer, chlorine e6 (Ce6), chemically conjugated to human serum albumin (HSA), the most abundant protein in human blood plasma.5 The conjugates form nontoxic, self-assembled nanoparticle structures (average diameter of 88 nm) in aqueous conditions. When illuminated by a 671 nm pulsed laser diode (to excite the Ce6 molecules), 600–700 nm fluorescence emission is detected using a fast photomultiplier tube (Hamamatsu) and a time-correlated single-photon counting system (Becker and Hickl GmbH). Essentially, photosensitizers are nontoxic to cells in the absence of light; however, when illuminated with a specific activating wavelength, they generate cytotoxic singlet oxygen that destroys target cells through apoptosis (programmed cell death) or necrosis. Photosensitized nanoparticles in solution penetrate the pores of newly generated vessels in tumor sites, killing the permeated cancer cells and demonstrating the theranostic efficacy of Ce6-HSA nanoparticles (see Fig. 2).
“Magnetic iron oxide nanoparticles [IONP] are becoming increasingly attractive as theranostic nanoparticles due to their low toxicity, stronger enhancement of protein relaxation, and lower detection limit in comparison with traditional gadolinium-based magnetic resonance [MR] contrast agents,” says Andrew Y. Wang, president of Ocean NanoTech (Springdale, AR). “These IONPs can generate heat to kill tumor cells in the presence of compatible radio frequencies, or be used as effective drug carriers owing to their large surface-to-volume ratio.”
|FIGURE 3. Transmission electron microscope (TEM) images show 10-nm-diameter iron oxide nanoparticles (IONPs), used for delivering chemotherapeutic drugs to cancerous tumors, as prepared in organic solvent (a) and dispersed in water (b). The white circles around the water-soluble IONPs are the organic coatings on the IONP surfaces used for drug loading. (Courtesy of Ocean NanoTech)|
Ocean NanoTech provides water-soluble, biocompatible, and very stable iron oxide nanoparticles to support research needs across the United States and has several ongoing collaborations, including a project with Emory University School of Medicine (Atlanta, GA) professors Lily Yang and Hui Mao to develop IONPs that can break the barriers in hard-to-penetrate pancreatic cancer tissues and deliver multiple chemotherapeutic drugs and small molecules into the tumor cells (see Fig. 3).6,7 One of the approaches loads the chemotherapeutic agent doxorubicin (Dox) to the IONP surface through hydrophobic interaction; each 10-nm-diameter IONP can load more than 600 Dox molecules. Another approach loads drugs to the IONP surface through pH change, heat, or enzyme application. This latter project is funded by the National Cancer Institute’s (NCI) Cancer Nanotechnology Platform Partnership (CNPP) program, which is dedicated to the advancement of new nanotechnology discoveries and their transformation into cancer-relevant applications with clinical utility.
With size-tunable emission spectra and stronger fluorescence (10–100X) with higher stability against photobleaching (10–1000X) compared to fluorescent proteins or organic fluorophores, quantum dots—typically 5–50 nm in diameter—are playing a significant role in theranostic applications.8
Researchers at the University of Bucharest (Bucharest, Romania) have developed a multifunctional nanoparticle platform encapsulating hydrophilic (water-soluble) quantum dots and chemotherapeutic agents.9 The drug gemcitabine, a nucleoside promoter of apoptosis, is dissolved in a chitosan solution together with cadmium sulfide (CdS) quantum dots. Nanoparticles 100 nm in diameter that can be administered intravenously are obtained by processing this polymeric solution using a water-in-oil microemulsion as the nanoreactor. These nanoparticles with complex morphology contain both imaging agents and drugs encapsulated in a biocompatible polymeric shell, easily functionalized to target cancer cells. The group is also working on hydrophobic (non-water-soluble) particles to reduce potential toxicity. “So far, the particles show strong fluorescence for imaging purposes, and drug delivery and uptake functionality is being assessed,” says University of Bucharest associate professor Ludmila Otilia Cinteza. “The theranostic concept seems to be a promising alternative to present cancer therapies. These multifunctional nanoparticles can simultaneously perform bioimaging for diagnostics, deliver drugs to the targeted tumor, and monitor the efficiency of the treatment.”
2. R. Bardhan et al., NanoLett., 10, 12, 4920–4928 (November 2010).
4. J.A. Schwartz et al., Lasers in Surgery and Medicine, 43, 213–220 (2011).
5. H. Jeong et al., Theranostics, 1, 230–239 (2011).
8. Y.-P. Ho and K.W. Leong, Nanoscale, 2, 60–68 (2010).
9. L. O. Cinteza, “Multifunctional nanosystems for cancer theragnostics,” SPIE Newsroom online; doi: 10.1117/ 2.1201103.003432 (Apr. 20, 2011).
Gail Overton is Senior Editor for Laser Focus World and a contributing editor for BioOptics World; firstname.lastname@example.org.